Fig. 3From: Gastrointestinal perforation after bevacizumab: a multi-site, single-institution study with a focus on survivalSurgical patients (red line) manifested a median survival of 6.9 months (95% confidence interval (CI) 2.2–13.6 months); whereas those who were not treated surgically manifested a survival of 1.45 months (95% CI 0.6–3.3 months), with a HR of 0.49 (95% CI 0.31–0.78); p = 0.003Back to article page